Summary: Significant progress has been made in the characterization of cartilage and bone differentiating proteins. A family of unique proteins known as bone morphogenetic proteins has been described, and there is ample evidence that they are directly responsible for de novo cartilage and bone formation in vivo. Extensive research is underway to develop appropriate and optimal delivery systems based on extracellular matrix components. It is likely that bone morphogenetic proteins will play a crucial role in bone and joint regeneration and repair.
Epithelial and Bone Matrix Induced Osteogenesis Demineralized Bone Matrix-Induced Osteogenesis
The bone has a remarkable potential for repair and regeneration. Regeneration processes such as fracture repair, recapitulate events that occur in the course of embryonic bone development. Experimental means of inducing new bone formation at non-bony sites have been known for years. In early 1930, Huggins (1) discovered that surgical transplantation of living urinary bladder epithelium into abdominal muscles in dogs resulted in new bone formation. The phenomenon was termed "epithelial Osteogenesis". Urist (2) and Reddi & Huggins (3) have shown that implantation of demineralized bone matrix into intramuscular or subcutaneous sites induced a sequence of cellular events leading to the formation of cartilage, bone, and bone marrow. The events were termed "matrix-induced endochondral bone formation". Inductive properties of demineralized bone matrix implantation at heterotopic sites are also reminiscent of embryonic bone development. It is believed that the putative molecules responsible for epithelial and matrix-induced Osteogenesis may have common structural properties, although this has not yet been demonstrated.
The cascade of matrix-induced endochondral bone formation consists of chemotaxis, attachment of mesenchymal stem cells to the matrix, proliferation of progenitor cells, and differentiation of cartilage ( fig. 1 ). This is followed by cartilage resorption, bone formation, and finally culminating in the formation of an ossicle filled with haematopoietic marrow (4). On day 1, fibronectin is deposited on the matrix facilitating cell attachment. On days 2 and 3, proliferation of mesenchymal cells takes place. This cell-matrix interaction results in the differentiation of chondroblasts at day 5, with appearance of cartilaginous matrix as shown by an increased 35 S (sulfate) incorporation into proteoglycans, and the appearance of hypertrophic chondrocytes at day 7. Angiogenesis with cartilage resorption starts on day 9, and new bone formation in association with 45 Ca incorporation into new bone mineral occurs at day 11 ( fig. 1 ). Extensive bone remodeling with haematopoietic marrow formation, as evidenced by 59 Fe incorporation, is maximal on day 21. This development programme is a single cycle of cartilage and bone formation, and recapitulates the embryonic development of limbs ( fig. 1 ). It could be a useful model for fracture healing. Moreover, this system enables molecular studies at the different stages of endochondral bone formation and a better understanding of the role of endogenous and exogenous growth and differentiation factors involved.
The Discovery of Osteogenin and other Bone Morphogenic Proteins
Identification of osteogenic proteins in mammalian bone matrix responsible for this cascade of cartilage and bone differentiation has been a difficult task due to the low abundance of osteogenin and related bone morphogenetic proteins tightly bound to the bone extracellular matrix. Progress in recent years in the study of bone morphogenetic proteins has been aided by four important technical developments, namely:
1. the development of a functional bioassay in a subcutaneous site in a rat to monitor the specific biology of osteogenic activity (5, 6); 2. the development of a specific purification procedure involving heparin affinity chromatography (7); 3. the use of electroendosmotic elution techniques after preparative sodium dodecyl sulfate gel electrophoresis to achieve final purification homogeneity (8) ; and 4. the use of recombinant DNA methodologies for the cloning and expression of several members of the bone morphogenetic proteins family (9) (10) (11) (12) .
A breakthrough in the isolation of osteogenic activity has been the dissociative extraction of demineralized bone matrix by 4 mol/1 guanidinium hydrochloride, or 8 mol/1 urea (5). Neither the soluble extract nor the residual bone powder alone had detectable activity when implanted subcutaneously in a rat. However, when the extract was reconstituted with the inactive residue, biological activity of bone and cartilage formation was recovered ( fig. 2 ). This reconstitution assay has permitted the further purification of osteogenic components. Additional experiments revealed that irrespective of the species, the lower molecular weight fractions of a 4 mol/1 guamdiniuin hydrochloride extract following molecular sieve chromatography induced new cartilage and bone formation in rats (5) . This discovery set the stage for the large scale purification of bone and cartilage inducing proteins.
A group of related bone morphogenetic factors has been discovered that include osteogenin, bone morphogenetic protein-2 (BMP-2), BMP-3, BMP-4, BMPs 5 and 6, osteogenic protein-1 (BMP-7), and osteogenic protein-2 (BMP-8) (8-11, 13, 14) . Osteogenin was purified to homogeneity from bovine bone matrix, and the sequences of several tryptic peptides were determined (8) .
The sequences were similar to portions of the amino acid sequence deduced from the cDNA clone of bone morphogenetic protein-3 (9) . Osteogenin shows 49 and 48% sequence identity in its carboxyl-terminal quarter to bone morphpgenetic protein-2 and bone morphogenetic protein-4, respectively (9) . Bone morphogenetic protein-7 was found to be identical to Osteogenic protein-1 (11, 14) . Based on structural and amino acid sequence homologies, these osteogenic proteins are grouped among members of the transforming growth factor β superfamily (tab. 1), all of which share a striking homology in the C-terminal domain ( fig. 3a ).
Osteogenin and related bone morphogenetic proteins initiate cartilage and bone formation in vivo. Bone morphogenetic protein-3 is most abundant in the highly purified preparations, but other members, especially bone morphogenetic protein-2 and bone morphogenetic protein-7 (osteogenic protein-1), are also present in the bioactive highly purified bone-derived fractions. Bone morphogenetic proteins 2-4 and bone morphogenetic protein-7 have been reported to induce cartilage and bone as single recombinant proteins in conjunction with residue (9, 11, 12, 14) . The availability of all the recombinant proteins will allow researchers to address the question of particular functions of different members in endochondral bone formation more accurately. The studies of the mechanism of action of the bone morphogenetic proteins will add considerable new information on the S-£ g δ S l molecular signals controlling cartilage and bone formation, as well as cartilage and bone regeneration.
As in the case of transforming growth factor-ß, members of transforming growth factor-ß superfamily are synthesized as a large precursor, four times greater than the mature form of the molecule. Members of this family encode secreted polypeptides that share common structural features ( fig. 3b ). They are proteolytically processed from the pro-protein to yield the carboxyl terminal mature proteins of approximately 110 amino acids as disulphide-linked homodimers. The active ligand form is a disulphide-bonded homodimer of a single family member or a heterodimer of two different members (15) (16) (17) . All members share a conserved pattern of seven highly conserved cystein residues.
Involvement of Bone Morphogenetic Proteins in Development
There is accumulating evidence that morphogenetic proteins are important regulators of many morphogenetic events during embryogenesis. For example, recent in situ hybridization studies for bone moiphogenetic protein-2, bone morphogenetic protein-4 and bone morphogenetic protein-6 revealed, in addition to the expected localization of transcripts in cells involved in skeletal morphogenesis, mRNA transcripts i'rf several extraskeletal organs and tissues, namely: the developing limb, the myogenic layer of the atrioventricular cushions of the developing heart, developing hair and whisker follicles, tooth buds and palate, developing central nervous system and craniofacial tissues (18) (19) (20) . Osteogenic protein-1 was identified in human placenta and in brain cDNA libraries (21) and by Northern hybridization analysis bone morphogenetic protein-3 to 6 mRNAs have been found in the lung (fig. 4) . Bone morphogenetic protein-3 message was found by in situ hybridization in perichondrium, periosteum/osteoblast layer, intestine, kidney and lung, which is a major site of synthesis during development (21, 22) .
By using Northern analysis and immunohistochemistry, osteogenic protein-1 was localized not only in osteo- image of (C). Arrow points to the ameloblast layer of the incisor corresponding brightfield section. Arrows indicate dental epithetooth. * genie sites, but also in kidney, adrenal, urinary bladder, developing heart and a number of basement membranes separating the epithelium from the underlying stroma (11, 13, 23) . Osteogenic protein-1 transcripts are present in a variety of tissues, suggesting local and/or systemic release, particularly in the development of kidney, limb bud, bone, tooth ( fig. 5 ), heart and intestine (24) .
These data together with the specific affinity of osteogenin and bone morphogenetic protein-2 for the type IV collagen of the basement membrane (25) , underscore the potential critical role of the extracellular matrix in sequestering differentiation factors and in regulating their bioavailability.
Involvement of Bone Morphogenetic Proteins in the Endochondral Bone Formation Cascade
In vitro studies allowed us to explore the effects of bone morphogenetic proteins on both cartilage and bone cells. Osteogenin stimulated alkaline phosphatase activity and collagen synthesis in rat periosteal cells and calvarial osteoblasts (26) . There was also an increase in the formation of alkaline phosphatase-positive colonies in rat bone marow stromal cell cultures (26) . The promotion of the osteogenic phenotype was confirmed in experiments with MC3T3-E1 osteoblastic cells; Osteogenin inhibited growth and stimulated alkaline phosphatase activity within 72 hours (27) , while usually about 12 days are needed for their spontaneous differentiation in vitro (28) . In the same cells, high-affinity receptors for bone morphogenetic protein-2 have been identified (29) . Several studies using either bone morphogenetic protein-2, 3 or 4 have confirmed and extended these original data on bone morphogenetic proteins promoting the osteoblastic phenotype (30) (31) (32) .
Chondrogenic activity of bone morphogenetic proteins A profound stimulation of proteoglycan synthesis in fetal rat chondroblasts and rabbit articular chondrocytes (26) , together with increased cartilage matrix synthesis in chick limb bud cell cultures (33) (34) , demonstrated the role of osteogenin in the promotion of the chondrogenic phenotype. Osteogenin and bone morphogenetic protein-4 were equipotent in the maintenance of proteoglycan metabolism in articular cartilage explant cultures of young, adolescent and adult tissues by increasing proteoglycan synthesis and decreasing proteoglycan catabolism (35) . Analysis of the newly synthesized proteoglycans, the glycosaminoglycan chain size, and the glycosaminoglycan type of explants treated with osteogenin or bone morphogenetic protein-4 indicated that they were very similar. Thus, both osteogenin and bone morphogenetic protein-4 alone are capable of stimulating and maintaining the chondrocyte phenotype in vitro (35) . Taken together, these in vitro data suggest that bone morphogenetic proteins play a role not only in the initiation of cartilage and bone formation, but clearly promote the expression and maintenance of the chondrogenic and osteogenic phenotype. The potential role of bone mo hogenetic proteins in healing cartilage defects is described later. It was found that osteogenic protein-1 (BMP-7) promotes cell proliferation and chondrocyte maturation without requiring either thyroid hormone or insulin, agents known to support chondrocyte differentiation in vitro. By comparison, transforming growth factor-ß and retinoic acid neither initiated nor promoted chondrocyte differentiation (36) .
Discovery and Potential Function of CartilageDerived Morphogenetic Proteins
Partially purified extracts from newborn calf articular cartilage were found to induce cartilage and bone when implanted subcutaneously in rats. This activity showed characteristics reminiscent of bone morphogenetic proteins. Degenerated oligonucleotide primer sets derived from the highly conserved carboxy-terminal region of the bone morphogenetic protein family were designed and used in reverse transcription-polymerase chain reactions with poly(A) + KNA from articular cartilage as template to determine which bone morphogenetic proteins are produced by chondrocytes. Two novel members of the transforming growth factor-ß superfamily were identified and designated as cartilage-derived morphogenetic protein-1 and -2. Their C-terminal transforming growth factor-ß domains are 82% identical, thus defining a novel subfamily most closely related to bone morphogenetic protein-5, bone morphogenetic protein-6 and osteogenic protein-1 ( fig. 3b ). Northern analyses showed that both genes are expressed predominantly in cartilaginous tissues. In situ hybridization and immunostaining showed that cartilage-derived morphogenetic protein-1 was found predominantly at the stage of precartilaginous mesenchymal condensation and throughout the cartilaginous cores of the developing long bones, whereas cartilage-derived morphogenetic protein-2 expression was restricted to the hypertrophic chondrocytes of ossifying long bone centers (37) . Neither gene was detectable in the axial skeleton during human embryonic development. The genetic map location for cartilage-derived morphogenetic protein-1 was defmefl on mouse chromosome 2 by Southern blot analysis of the progeny of two multilocus crosses. The cartilage-specific localization pattern of these novel transforming growth factor-ß superfamily members, which contrasts with the more ubiquitous presence of other bone morphogenetic protein family members, suggests a potential role for these proteins in chondrocyte differentiation and growth of long bones (37) . Moreover, recombinantly expressed cartilage-derived morphogenetic protein-1 induced cartilage at ectopic sites in rats (tab. 1). Several recombinantly expressed bone mqrphogenetic proteins can induce bone at ectopic sites in vivo (tab. 1). This apparent redundancy has gained much attention and recently it has been demonstrated that, apart from inducing bone development and regeneration, different bone morphogenetic proteins are the key mediators in initiating the development of parenchymatoüs organs; e. g. bone morphogenetic protein-4 mediation of tooth development (38) and osteogenic protein-1 initiation of kidney mesenchyme induction (Vukicevic et al., in preparation).
Potential Therapeutic Application of Bone Differentiation Factors
The availability of bone morphogenetie proteins has made it possible to extend the knowledge of their in vivo morphogenic potential in rodents to primates, a prerequisite for the exploration of potential therapeutic applications for the regeneration of bone in man. Craniofacial applications Table 2 shows the skeletal localization and the type of bone morphogenetic protein preparation used for experiments on the craniofacial skeleton.
First experiments on craniofacial regeneration were carried out using bovine native bone morphogenetic protein. Bone regeneration under the influence of a bone morphogenetic protein ß-tricalcium phosphate composite in skull trephine defects in dogs was investigated by Uns t et al. (39) . ß-Tricalcium phosphate was employed as a non-immunogenic biodegradable delivery system for bovine bone morphogenetic protein. Bone morphogenetic protein/ß-tricalcium phosphate implants induced 91-100% of new bone deposits (39, 40) . Ferguson et al. (41) proved that purified bovine bone morphogenetic protein induces repair of craniotomy defects. The morphogenetic responses included mesenchymal cell proliferation, chondrogenesis, and increased bone formation.
The healing potential of osteogenin on calvarial defects in a series of adult primates of genus Papio (baboon) has been studied. In 48 adult male baboons, calvarial defects were implanted with graft of autogenous bone harvested from the iliac crest, and with different osteoconductive and osteoinductive substrates (42) . Reconstitution of calvarial defects with baboon osteogenin induced huge amounts of new bone as early as 30 days. At 3 months, bone formation was extensive, culminating in complete regeneration of the craniotomy defects (43) (44) (45) (46) . A single application of human recombinant transforming growth factor-1 in a 3% methylcellulose gel to skull defects in New Zealand white rabbits induced a dose dependent increase in intramembranous bone formation (47) . Complete bony bridging of defects occurred within 28 days after treatment with 2 g of transforming growth factor-ßl. Transforming growth factor-ßl in contrast is not osteogenic when implanted with a carrier at orthotopic sites (7, 8, 48) .
Bone morphogenetic proteins were recently tested for their regenerating effects in human periodontal intrabony defects (49, 50) . Combined with insoluble collagenous bone matrix, bone morphogenetic proteins induced regeneration of cementum, periodontal ligament and alveolar bone in furcation defects created in adult baboons (50) . Periodontal regeneration is one of the major goals of periodontal therapy. The use of recombinant human bone morphogenetic proteins is in the experimental phase, but shows promise of increasing the regeneration of enamel and periodontal ligament and augmentation of mandibles (49, 50) .
Orthopaedic applications
Two preliminary reports on the treatment of large bony defects in human lower limbs by implants containing native human bone morphogenetic protein have been published. In the first, 12 patients with established nonunion of the femoral diaphysis junction received autogenous grafts or allografts with the preparation of purified bone morphogenetic protein (51) . Union was obtained in 11 of 12 cases at an average time of 4.7 months after grafting. The second report described 6 patients with segmental tibial defects, 3 to 17 cm long, who obtained solid bony union after implantation of bone morphogenetic protein and autogenous bone grafts (52) . The osteogenic effect of bone morphogenetic protein in such The possibility of using bone morphogenetic proteins in spinal fusion has been carefully explored. The efficacy of recombinant human bone morphogenetic protein-2 delivered in a porous biodegradable copolymer, poly-(Z),Z,-lactide-coglycide) was evaluated using a canine posterior segmental spinal fusion model (56, 57) . Union score and mechanical testing showed no difference between autogenous cancellous bone and recombinant human bone morphogenetic protein-2. These findings suggest that synthetic bone graft substitutes delivering recombinant human bone morphogenetic protein-2 may be suitable for posterior spinal fusions. The results obtained on a similar model by Cook et al. (58) indicated that recombinant human osteogenic protein-1 is an effective bone graft substitute for achieving stable posterior spinal fusion in a significantly more rapid fashion than can be achieved with autogenous bone graft. The results reported by Boden (59) and those of Sandhy et al. (60) confirmed that bone morphogenetic proteins may serve as powerful bone graft substitutes for lumbar spine fusion.
The possibility of using bone morphogenetic protein for the enhancement of osseous growth during implantation of cementless endoprothesis of hip and knee joints has also been the subject of preliminary clinical investigations. Bone morphogenetic proteins have proven both their osteoinductive and osteoconductive potentials as well as exceptional tolerance and immunological inertness. At present, clinical trials on human patients are being conducted. At this point in time, the greatest problem is the unresolved question of the carrier substance and delivery system.
The carrier for bone morphogenetic proteins Carrier substrates will have to meet the following requirements:
1) relative insolubility in physiological conditions; 2) biodegradability; 3) protection against proteolytic activities; 4) function as substrate for cell adhesion and proliferation; 5) be immunologically inert; 6) achieve a slow release of a bone morphogenetic protein through controlled biological degradation, and 7) have mechanical stability in rebridging bony defects.
Some of these qualities are in part fulfilled by the various organic and inorganic materials which have been used as bone morphogenetic protein carriers (tab. 4) but this problem has not yet been completely solved by any research group. The fulfilment of the ideal properties of an osteoinductive material, based on synthetic or natural carrier, is a promising challenge for biomaterial research.
Definitive evaluation of the clinical use of bone morphogenetic protein will be possible after all the different factors influencing implant activity have been elucidated, and after development of an appropriate carrier.
